AbbVie looks beyond Humira with Botox-maker Allergan

Reuters - Business (Amazon FireTV)
06/25/2019 | 2 min | NOT-RATED
Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan for about $63 billion, grabbing control of the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. Fred Katayama reports.